

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited

再鼎醫藥有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF THIRD QUARTER 2021 RESULTS ANNOUNCEMENT

Our board of directors will consider for approval, among other matters, our unaudited quarterly results for the nine months ended September 30, 2021 (“**Results**”) on Wednesday, November 10, 2021 (China Standard Time). If approved, we will announce our Results at or around 8:00 a.m. on Wednesday, November 10, 2021 (China Standard Time) on the website of the Hong Kong Stock Exchange at www.hkexnews.hk and the website of Zai Lab Limited (the “**Company**”) at www.zailaboratory.com.

After the Results have been approved and released, our management plans to host a live earnings teleconference call and webcast on Wednesday, November 10, 2021 (China Standard Time) to discuss the Results and answer questions. Interested parties may access the live webcast via the Company’s website at <http://ir.zailaboratory.com>. Participants must register in advance of the conference call through the link provided below. Upon registering, each participant will be provided with participant dial-in number, a passcode and a unique access PIN.

Registration link: <http://apac.directeventreg.com/registration/event/9666772>
Conference ID: 9666772

A replay will be available shortly after the call and can be accessed by visiting the Company’s website at <http://ir.zailaboratory.com>.

By order of the Board

Zai Lab Limited

Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, October 28, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth and Mr. Scott W. Morrison as the independent directors.

* For identification only